Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
about
Genomic assays for Epstein-Barr virus-positive gastric adenocarcinomaViral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolutionHLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02.The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected CellsEmerging roles for RNA degradation in viral replication and antiviral defense.Immune control of oncogenic γ-herpesviruses.Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-IIInduction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China.Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis.Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection
P2860
Q27024034-68B919DF-61E4-41BE-8271-E2C1B39BF72EQ28083232-6F1CF7A4-A052-4EE1-83A8-C58578D5A92BQ35742269-8B631CEB-281E-4555-A14C-56DA3727BC57Q35989470-5C575417-2DD6-45D0-A059-E75FCCD28566Q38365673-F02F045D-F6D3-4A96-A98B-01842D7D06EEQ38587362-120DB24D-249B-482A-B3F9-6B8AFCCB89D5Q38718440-0FA5835D-FFE5-49F9-9770-4B5BF464F130Q38827812-5D97001D-04E1-4813-A188-71C58201CFDDQ40922609-48DCD336-A1C6-410D-8DB9-2603F44EF0E6Q40955418-62371091-3DF7-4D44-ACB1-D2A37413FD2BQ45325411-3E585DAD-1729-4DAE-9287-237F846E2867Q54245037-2DEB334F-229F-4C6D-BF18-622F8798B48CQ54248129-536B7E50-5944-4904-9A99-0CC4E0D4866AQ58699977-502BD061-8A3C-4D8F-9E2F-BD452065151F
P2860
Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cooperation between Epstein-Ba ...... ree phases of the lytic cycle.
@en
type
label
Cooperation between Epstein-Ba ...... ree phases of the lytic cycle.
@en
prefLabel
Cooperation between Epstein-Ba ...... ree phases of the lytic cycle.
@en
P2093
P2860
P50
P1433
P1476
Cooperation between Epstein-Ba ...... ree phases of the lytic cycle.
@en
P2093
Andrew D Hislop
Claire Shannon-Lowe
Laura L Quinn
Rosemary J Tierney
P2860
P304
P356
10.1371/JOURNAL.PPAT.1004322
P577
2014-08-21T00:00:00Z